Literature DB >> 12646795

Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.

Robert P Myers1, Yves Benhamou, Françoise Imbert-Bismut, Vincent Thibault, Marie Bochet, Frédéric Charlotte, Vlad Ratziu, François Bricaire, Christine Katlama, Thierry Poynard.   

Abstract

OBJECTIVE: Liver biopsy, the gold standard for assessing hepatitis C virus (HCV)-related fibrosis, is invasive and prone to complications. Our aim was to determine the operating characteristics of a non-invasive index of biochemical markers for the prediction of fibrosis in patients with HIV/HCV co-infection.
DESIGN: In a cross-sectional, cohort study in a French tertiary-care hospital 130 HIV/HCV-co-infected patients with a liver biopsy and serum were tested for markers of liver fibrosis.
METHODS: An index incorporating age, sex, alpha(2)-macroglobulin, apolipoprotein A1, haptoglobin, bilirubin, and gamma-glutamyl-transpeptidase (GGT), derived using multivariate logistic regression, was compared with liver histology. HIV-specific indices including the CD4 cell count and HIV-RNA load were also constructed. The diagnostic values of the indices were compared using receiver operating characteristic (ROC) curves. MAIN OUTCOME MEASURE: Septal fibrosis (F2-F4) by the METAVIR classification.
RESULTS: By multivariate analysis, the most informative markers were alpha(2)-macroglobulin, apolipoprotein A1, GGT, and sex. The area under the ROC curve of the five-marker index was 0.856 +/- 0.035; not significantly different from the HIV-specific indices. On a scale from zero to 1.00, the five-marker index had a positive predictive value of 86% for scores greater than 0.60, and a negative predictive value of 93% for scores of 0.20 or less. These thresholds could reduce the necessity for liver biopsy by 55% while maintaining an accuracy of 89%.
CONCLUSION: An index including five biochemical markers accurately predicts significant fibrosis in patients with HIV/HCV co-infection, and may substantially reduce the necessity for liver biopsy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12646795     DOI: 10.1097/00002030-200303280-00010

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  37 in total

Review 1.  Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care.

Authors:  Andrew J Muir
Journal:  Top Antivir Med       Date:  2014 Sep-Oct

2.  Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes.

Authors:  J Macías; J A Girón-González; M González-Serrano; D Merino; P Cano; J A Mira; A Arizcorreta-Yarza; J Ruíz-Morales; J M Lomas-Cabeza; J A García-García; J E Corzo; J A Pineda
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

3.  Update on Hepatitis B and C Coinfection in HIV.

Authors:  Patrick Yachimski; Raymond T Chung
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

4.  Effective use of FibroTest to generate decision trees in hepatitis C.

Authors:  Dana Lau-Corona; Luís Alberto Pineda; Héctor Hugo Avilés; Gabriela Gutiérrez-Reyes; Blanca Eugenia Farfan-Labonne; Rafael Núñez-Nateras; Alan Bonder; Rosalinda Martínez-García; Clara Corona-Lau; Marco Antonio Olivera-Martínez; Maria-Concepción Gutiérrez-Ruiz; Guillermo Robles-Díaz; David Kershenobich
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

Review 5.  After the cure: management of HCV after achievement of SVR.

Authors:  Zachary A Zator; Raymond T Chung
Journal:  Curr HIV/AIDS Rep       Date:  2013-12       Impact factor: 5.071

6.  Clinical Utility of Biomarkers of Liver Fibrosis.

Authors:  Keyur Patel; Don C Rockey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

Review 7.  Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.

Authors:  Eleanor M Wilson; Elana S Rosenthal; Sarah Kattakuzhy; Lydia Tang; Shyam Kottilil
Journal:  Clin Microbiol Rev       Date:  2016-10-19       Impact factor: 26.132

8.  HIV coinfection with hepatitis C and hepatitis B.

Authors:  Jenny O Smith; Richard K Sterling
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

9.  Use of the AST to platelet ratio index in HCV/HIV co-infected patients.

Authors:  A G Singal; L V Thomassen; D R Gretch; M C Shuhart
Journal:  Aliment Pharmacol Ther       Date:  2011-01-05       Impact factor: 8.171

Review 10.  Role of liver biopsy in the era of direct-acting antivirals.

Authors:  Humberto C Gonzalez; Syed Mohammed Jafri; Stuart C Gordon
Journal:  Curr Gastroenterol Rep       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.